We are studying the role of the complement system in kidneys and brains during health and disease. Traditionally, major complement proteins were shown to be generated by the liver and are functional ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
News-Medical.Net on MSN
Mitochondria and lysosomes work together to control regulatory T cell activation
Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback